The purpose of the study was to investigate the dynamics of endothelial monocyte activating polypeptide-ІІ in patients with acute myocardial infarction with concomitant diabetes mellitus type 2 six months after a coronary event. Materials and methods. 120 patients participated in the study: group 1 – patients with acute myocardial infarction with diabetes mellitus type 2 (n=70), group 2 – patients with acute myocardial infarction (n=50). The control group included 20 practically healthy people. All patients underwent laboratory and instrumental examination on the first day of acute myocardial infarction and 6 months after it. The level of endothelial monocyte activating polypeptide-ІІ was determined using the test system “Human Endothelial Monocyte Activating Polypeptide-ІІ ELISA KIT”. Results and discussion. The average level of endothelial monocyte activating polypeptide-ІІ on the first day of an acute myocardial infarction was: in patients who were part of the 1st group – 4.54 ± 0.331 ng/ml; 2nd – 2.74 ± 0.21 ng/ml; control group – 1.1 ± 0.037 ng/ml (р<0.05). In patients of the 1st group, half a year after acute myocardial infarction, the average level of endothelial monocyte activating polypeptide-ІІ was equal to 3.6 ± 0.11 ng/ml; 2nd – 2.28 ± 0.05 ng/ml (р<0.00001). Re-examination of patients, depending on treatment tactics, showed the following results: in patients with acute myocardial infarction with concomitant diabetes mellitus type 2 after cardiac ventriculography, the endothelial monocyte activating polypeptide-ІІ level was equal to 3.5 ± 0.04 ng/ml; in patients with acute myocardial infarction with concomitant diabetes mellitus type 2 after standard anticoagulant therapy it was 3.71 ± 0.03 ng/ml; in patients with isolated acute myocardial infarction after cardiac ventriculography – 2.24 ± 0.01 ng/ml; in patients with isolated acute myocardial infarction after standard anticoagulant therapy – 2.33 ± 0.04 (р<0.01). Conclusion. Endothelial monocyte activating polypeptide-ІІ is a marker of endothelial dysfunction that has prognostic properties in relation to comorbid pathology in the form of acute myocardial infarction with. diabetes mellitus type 2. In patients with an acute myocardial infarction in the presence of diabetes mellitus type 2, a higher level of endothelial monocyte activating polypeptide-ІІ was noted on the 1st day of a coronary event and 6 months after it, compared to patients with an isolated acute myocardial infarction and individuals of the control group (p<0.05). After cardiac ventriculography in patients, the level of endothelial monocyte activating polypeptide-ІІ was significantly lower compared to this indicator after standard anticoagulant therapy

Keywords: endothelial monocyte activating polypeptide-ІІ, markers of endothelial dysfunction, comorbid pathology, acute myocardial infarction, diabetes mellitus type 2

Full text: PDF (Ukr) 294K

1. Incalza MA, D'Oria R, Natalicchio A, Perrini S, Laviola L., Giorgino F. Oxidative stress and reactive oxygen species in endothelial dysfunction associated with cardiovascular and metabolic diseases. Vascul Pharmacol. 2018 Jan;100:1-19. PMID: 28579545. doi: 10.1016/j.vph.2017.05.005
2. Silva FC, Araújo BJ, Cordeiro CS, Arruda VM, Faria BQ, Guerra JFDC, et al. Endothelial dysfunction due to the inhibition of the synthesis of nitric oxide: Proposal and characterization of an in vitro cellular model. Front Physiol. 2022 Nov 17;13:978378. PMID: 36467706. PMCID: PMC9714775. doi: 10.3389/fphys.2022.978378
3. Haybar H, Shahrabi S, Rezaeeyan H, Shirzad R, Saki N. Endothelial Cells: From Dysfunction Mechanism to Pharmacological Effect in Cardiovascular Disease. Cardiovasc Toxicol. 2019 Feb;19(1):13-22. PMID: 30506414. doi: 10.1007/s12012-018-9493-8
4. Alisa MС. Endothelial response to glucose: dysfunction, metabolism, and transport. Biochem Soc Trans. 2021 Feb 26;49(1):313-325. PMID: 33522573. PMCID: PMC7920920. doi: 10.1042/BST20200611
5. Kaur R, Kaur M, Singh J. Endothelial dysfunction and platelet hyperactivity in type 2 diabetes mellitus: molecular insights and therapeutic strategies. Cardiovasc Diabetol. 2018 Aug 31;17(1):121. PMID: 30170601. PMCID: PMC6117983. doi: 10.1186/s12933-018-0763-3
6. Wiggenhauser LM, Kroll J. Vascular Damage in Obesity and Diabetes: Highlighting Links Between Endothelial Dysfunction and Metabolic Disease in Zebrafish and Man. Curr Vasc Pharmacol. 2019;17(5):476-490. PMID: 30378499. doi: 10.2174/1570161116666181031101413
7. Sáez T, Toledo F, Sobrevia L. Extracellular Vesicles and Insulin Resistance: A Potential Interaction in Vascular Dysfunction. Affiliations Expand. PMID: 30277159. doi: 10.2174/1570161116666181002095745
8. Mohylnytska LA. Serum levels of endothelial monocyte-activating polypeptide-II in type 2 diabetes mellitus. Fiziol Zh. 2014;60(1):84-90. PMID: 24809179
9. Mogylnytska LA. Endothelial monocyte-activating polypeptide-II: properties, functions, and pathogenetic significance. Fiziol Zh. 2015;61(1):102-11. PMID: 26040042. doi: 10.15407/fz61.01.102
10. Saber ММ. EMAP II Expression Is Increased on Peripheral Blood Cells from Non-Hodgkin Lymphoma. J Immunol Res. 2022 Sep 12;2022:7219207. PMID: 36132984. PMCID: PMC9484964. doi: 10.1155/2022/7219207
11. Mіnіsterstvo ohoroni zdorov’ya Ukraїni, Nakaz № 455. Unіfіkovanij klіnіchnij protokol ekstrenoї, pervinnoї, vtorinnoї (specіalіzovanoї) ta tretinnoї (visokospecіalіzovanoї) medichnoї dopomogi ta medichnoї reabіlіtacії «Gostrij koronarnij sindrom z elevacіeyu segmenta ST» [Unified clinical protocol of emergency, primary, secondary (specialized) and tertiary (highly specialized) medical care and medical rehabilitation "Acute coronary syndrome with elevation of the ST segment"]. K: Ministry of Health of Ukraine; 2014 July 2. p. 92. [Ukrainian]
12. Mіnіsterstvo ohoroni zdorov’ya Ukraїni, Nakaz № 1957. Unіfіkovanij klіnіchnij protokol ekstrenoї, pervinnoї, vtorinnoї (specіalіzovanoї) ta tretinnoї (visokospecіalіzovanoї) medichnoї dopomogi ta medichnoї reabіlіtacії «Gostrij koronarnij sindrom bez elevacії ST» [Ministry of Health of Ukraine, Order No. 1957. Unified clinical protocol of emergency, primary, secondary (specialized) and tertiary (highly specialized) medical care and medical rehabilitation "Acute coronary syndrome without ST elevation"]. K: Ministry of Health of Ukraine; 2021 September 15. 62 p. [Ukrainian]
13. Mіnіsterstvo ohoroni zdorov’ya Ukraїni, Nakaz № 1118. Unіfіkovanij klіnіchnij protokol pervinnoї ta vtorinnoї (specіalіzovanoї) medichnoї dopomogi «Cukrovij dіabet 2 tipu» [Ministry of Health of Ukraine, Order No. 1957. Unified clinical protocol of primary and secondary (specialized) medical care "Diabetes mellitus type 2""]. K: Ministry of Health of Ukraine; ; 2012 December 21. 115p. [Ukrainian]
14. Yuan С, Yan L, Solanki P, Vatner SF, Vatner DE, Schwarz MA. Blockade of EMAP II protects cardiac function after chronic myocardial infarction by inducing angiogenesis. J Mol Cell Cardiol. 2015 Feb;79:224-31. PMID: 25456857. PMCID: PMC4302026. doi: 10.1016/j.yjmcc.2014.11.021
15. Mogylnytska LA. Serum level of endothelial monocyte activating polypeptide-II in childhood-onset type 1 diabetic patients and obese adolescents. Lik Sprava. 2015 Jul-Sep;(5-6):51-7. PMID: 27089716
16. Adly ААМ, Ismail EA, Tawfik LM, Ebeid FSE, Hassan Asmaa AS. Endothelial monocyte activating polypeptide II in children and adolescents with type 1 diabetes mellitus: Relation to micro-vascular complications. Cytokine. 2015 Dec;76(2):156-162. PMID: 26142824. doi: 10.1016/j.cyto.2015.06.006